
    
      This study is conducted to assess the effect of metformin addition to the chemotherapy
      protocol of non-diabetic breast cancer patients compared to the control group (non-metformin
      users) in the neoadjuvant setting. Evaluation of the the clinical benefit rate and the rate
      of pathological complete response will be conducted. In addition, a correlation between the
      beneficial effect of metformin and the serum concentration of metformin. Also, a comparison
      in the quality of life between the metformin group and the control group will be evaluated
      using the European Organization for Research and Treatment of Cancer Quality of Life
      Questionnaire (EORTC QLQ C30) and (EORTC QLQ BR45) questionnaires will be done.
    
  